05 Jun Novo Nordisk and Eli Lillys GLP-1s investment case just became even more compelling As published in FA News on 30 May 2024 By Philip Short Flagship Asset Management fund manager The investment case for Novo Nordisk and Eli Lilly became even more compelling last week after a study found that the fast-selling weight loss GLP-1 drug semaglutide, sold as Ozempic and Wegovy, helps protect the kidney function of overweight or heart disease patients
Willows site does carry the FDA compounding line: When made according to federal laws, compounded drugs do not require FDA approval and are exempt from undergoing safety, effectiveness, or manufacturing reviews. Credit for putting that disclaimer where patients can read it
Shake gently before each use
The study highlights BPC-157s ability to counteract such neurological disturbances in rats by acting as a radical scavenger, which helps neutralize damaging agents in the test animals
Each weekly dose from 0.25mg2.4mg draws less than 0.5mL, keeping injection volume comfortable
These may include: Muscle cramps or weakness Increased heart rate Seizures in individuals with seizure disorders Worsening of hypothyroid symptoms Gastrointestinal discomfort in sensitive individuals If any of these symptoms occur, its important to discontinue use and seek medical advice immediately